These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 27473084)

  • 1. ASPP2 suppresses stem cell-like characteristics and chemoresistance by inhibiting the Src/FAK/Snail axis in hepatocellular carcinoma.
    Xu L; Tong X; Zhang S; Yin F; Li X; Wei H; Li C; Guo Y; Zhao J
    Tumour Biol; 2016 Oct; 37(10):13669-13677. PubMed ID: 27473084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-192, a prognostic indicator, targets the SLC39A6/SNAIL pathway to reduce tumor metastasis in human hepatocellular carcinoma.
    Lian J; Jing Y; Dong Q; Huan L; Chen D; Bao C; Wang Q; Zhao F; Li J; Yao M; Qin L; Liang L; He X
    Oncotarget; 2016 Jan; 7(3):2672-83. PubMed ID: 26684241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling.
    Yin X; Zhang BH; Zheng SS; Gao DM; Qiu SJ; Wu WZ; Ren ZG
    J Hematol Oncol; 2015 Mar; 8():23. PubMed ID: 25879771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
    Zhai B; Zhang X; Sun B; Cao L; Zhao L; Li J; Ge N; Chen L; Qian H; Yin Z
    Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of PRRX1 Confers Cancer Stem Cell-Like Properties and Predicts Poor Prognosis in Hepatocellular Carcinoma.
    Hirata H; Sugimachi K; Takahashi Y; Ueda M; Sakimura S; Uchi R; Kurashige J; Takano Y; Nanbara S; Komatsu H; Saito T; Shinden Y; Iguchi T; Eguchi H; Atsumi K; Sakamoto K; Doi T; Hirakawa M; Honda H; Mimori K
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1402-9. PubMed ID: 25404478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Notch and Wnt/β-catenin signaling pathway play important roles in activating liver cancer stem cells.
    Wang R; Sun Q; Wang P; Liu M; Xiong S; Luo J; Huang H; Du Q; Geller DA; Cheng B
    Oncotarget; 2016 Feb; 7(5):5754-68. PubMed ID: 26735577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total alkaloids of Rubus aleaefolius Poir. inhibit the STAT3 signaling pathway leading to suppression of proliferation and cell cycle arrest in a mouse model of hepatocellular carcinoma.
    Zhao J; Lin W; Cao Z; Liu L; Zhuang Q; Zhong X; Hong Z; Peng J
    Oncol Rep; 2013 Sep; 30(3):1309-14. PubMed ID: 23828071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of ASPP2 in choriocarcinoma contributes to increased migratory potential through Src signaling pathway activation.
    Mak VC; Lee L; Siu MK; Wong OG; Lu X; Ngan HY; Wong ES; Cheung AN
    Carcinogenesis; 2013 Sep; 34(9):2170-7. PubMed ID: 23671128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of transcription factor Ikaros on the expression of liver cancer stem cell marker CD133 in hepatocellular carcinoma.
    Zhang L; Li H; Ge C; Li M; Zhao FY; Hou HL; Zhu MX; Tian H; Zhang LX; Chen TY; Jiang GP; Xie HY; Cui Y; Yao M; Li JJ
    Oncotarget; 2014 Nov; 5(21):10621-35. PubMed ID: 25301737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Artemin is hypoxia responsive and promotes oncogenicity and increased tumor initiating capacity in hepatocellular carcinoma.
    Zhang M; Zhang W; Wu Z; Liu S; Sun L; Zhong Y; Zhang X; Kong X; Qian P; Zhang H; Lobie PE; Zhu T
    Oncotarget; 2016 Jan; 7(3):3267-82. PubMed ID: 26675549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ack1 overexpression promotes metastasis and indicates poor prognosis of hepatocellular carcinoma.
    Lei X; Li YF; Chen GD; Ou DP; Qiu XX; Zuo CH; Yang LY
    Oncotarget; 2015 Dec; 6(38):40622-41. PubMed ID: 26536663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
    Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
    PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic silence of ankyrin-repeat-containing, SH3-domain-containing, and proline-rich-region- containing protein 1 (ASPP1) and ASPP2 genes promotes tumor growth in hepatitis B virus-positive hepatocellular carcinoma.
    Zhao J; Wu G; Bu F; Lu B; Liang A; Cao L; Tong X; Lu X; Wu M; Guo Y
    Hepatology; 2010 Jan; 51(1):142-53. PubMed ID: 20034025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capn4 contributes to tumour growth and metastasis of hepatocellular carcinoma by activation of the FAK-Src signalling pathways.
    Dai Z; Zhou SL; Zhou ZJ; Bai DS; Xu XY; Fu XT; Chen Q; Zhao YM; Zhu K; Yu L; Yang GH; Wang Z; Wu WZ; Zhou J; Fan J
    J Pathol; 2014 Nov; 234(3):316-28. PubMed ID: 24962955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-149 represses metastasis of hepatocellular carcinoma by targeting actin-regulatory proteins PPM1F.
    Luo G; Chao YL; Tang B; Li BS; Xiao YF; Xie R; Wang SM; Wu YY; Dong H; Liu XD; Yang SM
    Oncotarget; 2015 Nov; 6(35):37808-23. PubMed ID: 26498692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
    Su JC; Chiang HC; Tseng PH; Tai WT; Hsu CY; Li YS; Huang JW; Ko CH; Lin MW; Chu PY; Liu CY; Chen KF; Shiau CW
    Carcinogenesis; 2014 Dec; 35(12):2807-14. PubMed ID: 25322871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma.
    Wang F; Feng Y; Li P; Wang K; Feng L; Liu YF; Huang H; Guo YB; Mao QS; Xue WJ
    Oncotarget; 2016 Jan; 7(4):4279-97. PubMed ID: 26701853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway.
    Zhao H; Guo Y; Li S; Han R; Ying J; Zhu H; Wang Y; Yin L; Han Y; Sun L; Wang Z; Lin Q; Bi X; Jiao Y; Jia H; Zhao J; Huang Z; Li Z; Zhou J; Song W; Meng K; Cai J
    Oncotarget; 2015 Oct; 6(31):31927-43. PubMed ID: 26376676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
    Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
    Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma.
    Tomuleasa C; Soritau O; Rus-Ciuca D; Pop T; Todea D; Mosteanu O; Pintea B; Foris V; Susman S; Kacsó G; Irimie A
    J Gastrointestin Liver Dis; 2010 Mar; 19(1):61-7. PubMed ID: 20361077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.